Clinical trials: Urologic Neoplasms
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory…
- Conditions
- Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary Hypercalcemic Type
- Trial name
- NCT03874455
- Testing
- Tazemetostat
- Sponsor
- Epizyme, Inc.
Bladder Cancer
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or…
- Trial name
- SunRISe-3 (NCT05714202)
- Testing
- TAR-200, Cetrelimab, BCG Vesiculture
- Where
- 240 sites in United States, Argentina and 19 more
- Volunteers
- 1,135 people
- Sponsor
- Janssen Research & Development, LLC
Clear Cell Renal Cell Carcinoma
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer…
- Trial name
- NCT02923531
- Testing
- X4P-001, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- X4 Pharmaceuticals
Renal Insufficiency, Hemodialysis
A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)
A study to evaluate the effect of kidney disease, from mild to severe disease, on a diabetes medication
- Trial name
- NCT00418366
- Testing
- MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Urological Cancer, Solid Cancer
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and dose-expansion, non-randomized phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036…
- Trial name
- NCT07744243
- Testing
- SI-B036
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Hormone-sensitive Prostate Cancer
An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care
This is an observational study in which only data are collected from adult Canadian men with metastatic hormone sensitive prostate cancer (mHSPC) are studied.
- Trial name
- RE-ENGAGE (NCT06874114)
- Where
- Canada
- Volunteers
- 477 people
- Sponsor
- Bayer
Non Muscle Invasive Bladder Cancer, Bladder Cancer
Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients
This is a Phase II, prospective, single-arm, open-label clinical study evaluating hyperthermic intravesical chemotherapy (HIVEC) with Mitomycin C in patients with high-grade, non-muscle-invasive bladder cancer (NMIBC) who are…
- Conditions
- Non Muscle Invasive Bladder Cancer, Bladder Cancer, Carcinoma in Situ of Bladder, Urinary Bladder Neoplasms
- Trial name
- HIVEC (NCT07231809)
- Testing
- Hyperthermic Intravesical Chemotherapy (HIVEC)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- AC.TA. S.r.l.
Metastatic Renal Cell Carcinoma
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacodynamics, of Panzem® NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on…
- Trial name
- NCT00444314
- Testing
- Panzem® NCD, Sunitinib Malate
- Where
- 3 sites in United States
- Volunteers
- 82 people
- Sponsor
- CASI pharmaceuticals, Inc.
Chronic Renal Failure
The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis
To investigate the biocompatibility of the peritoneal dialysis (PD) solution balance in comparison to the conventional PD solution in APD(automated peritoneal dialysis) patients using the APD cycler sleep•safe.
- Trial name
- NCT01753154
- Testing
- Solution B (balance PD solution), Solution A (conventional PD solution)
- Where
- 7 sites in Poland, Spain
- Volunteers
- 25 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Metastatic Renal Cell Carcinoma
Sutent Rechallenge In mRCC Patients
Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.
- Trial name
- RESUME (NCT01827254)
- Testing
- sunitinib: observational study
- Where
- 18 sites in France
- Volunteers
- 61 people
- Sponsor
- Pfizer
Advanced Solid Tumors, Metastatic Breast Cancer
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Study has two parts: 1. Dose-finding: to determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of RAD001 (everolimus , Afinitor®) in combination with BEZ235 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
- Trial name
- NCT01482156
- Testing
- RAD001 + BEZ235
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
The purpose of this study is to see if taking interferon or gemcitabine along with sorafenib will stop the advanced renal cell cancer from becoming worse in some people.
- Trial name
- NCT00352859
- Testing
- Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon, Gemcitabine or Interferon (only)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bayer
Carcinoma, Renal Cell
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
This study is to assess sorafenib as second treatment for patients that have previously received only sunitinib as first-line treatment for advanced renal cell cancer, and who either responded and then progressed with sunitinib…
- Trial name
- NCT00678288
- Testing
- Sorafenib (Nexavar, BAY43-9006), Sorafenib (Nexavar, BAY43-9006) + Interferon
- Where
- 35 sites in Austria, France and 5 more
- Volunteers
- 16 people
- Sponsor
- Bayer
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
This study will be conducted in adult subjects diagnosed with any form of an advanced or metastatic solid tumors including urothelial carcinoma for which standard therapy is no longer effective or is intolerable.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Bladder Cancer, Bladder Disease
- Trial name
- NCT04200963
- Testing
- IK-175, IK-175 and nivolumab
- Where
- 10 sites in United States
- Volunteers
- 78 people
- Sponsor
- Ikena Oncology
Renal Cell Carcinoma
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
To assess how dose reductions or treatment interruptions related to axitinib can be implemented to manage and resolve adverse events occurring among patients with advanced renal cell carcinoma treated with first-line axitinib in…
- Trial name
- NCT04682587
- Testing
- Axitinib, Avelumab, Pembrolizumab
- Where
- United States
- Volunteers
- 481 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Renal Cell Carcinoma
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
The primary objective of the study is to determine whether participants exhibit a measurable immune response after multiple administrations of HSPPC-96 (heat shock protein-peptide complex 96), as assessed by enzyme linked…
- Trial name
- NCT01147536
- Testing
- HSPPC-96
- Where
- 3 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Agenus Inc.
Bladder Cancer
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery.
- Trial name
- NCT00303654
- Testing
- biopsy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roei Medical Technologies Ltd.
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Urothelial Carcinoma
A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
A multicenter ambispective (retrospective and prospective) non-interventional study of patients with locally advanced or metastatic urothelial carcinoma (adv/mUC) treated with avelumab in France, not impacting the treatment…
- Trial name
- AVENANCE (NCT04822350)
- Testing
- Avelumab
- Where
- 81 sites in France
- Volunteers
- 596 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.